OR WAIT null SECS
© 2021 MJH Life Sciences and Psychiatric Times. All rights reserved.
© 2021 MJH Life Sciences™ and Psychiatric Times. All rights reserved.
October 21st 2021
Drs Harding and Halaris evaluate the phase 3 TRANSFORM trial that studied intranasal esketamine as a therapy option for treatment resistant depression.